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Abstract
Cannabis use and disorders (CUD) are influenced by multiple genetic variants of small effect and by the psychosocial
environment. However, this information has not been effectively incorporated into studies of gene–environment
interaction (GxE). Polygenic risk scores (PRS) that aggregate the effects of genetic variants can aid in identifying the
links between genetic risk and psychosocial factors. Using data from the Pasman et al. GWAS of cannabis use (meta-
analysis of data from the International Cannabis Consortium and UK Biobank), we constructed PRS in the Collaborative
Study on the Genetics of Alcoholism (COGA) participants of European (N: 7591) and African (N: 3359) ancestry. The
primary analyses included only individuals of European ancestry, reflecting the ancestral composition of the discovery
GWAS from which the PRS was derived. Secondary analyses included the African ancestry sample. Associations of PRS
with cannabis use and DSM-5 CUD symptom count (CUDsx) and interactions with trauma exposure and frequency of
religious service attendance were examined. Models were adjusted for sex, birth cohort, genotype array, and ancestry.
Robustness models were adjusted for cross-term interactions. Higher PRS were associated with a greater likelihood of
cannabis use and with CUDsx among participants of European ancestry (p < 0.05 and p < 0.1 thresholds, respectively).
PRS only influenced cannabis use among those exposed to trauma (R2: 0.011 among the trauma exposed vs. R2: 0.002
in unexposed). PRS less consistently influenced cannabis use among those who attend religious services less
frequently; PRS × religious service attendance effects were attenuated when cross-term interactions with ancestry and
sex were included in the model. Polygenic liability to cannabis use was related to cannabis use and, less robustly,
progression to symptoms of CUD. This study provides the first evidence of PRS × trauma for cannabis use and
demonstrates that ignoring important aspects of the psychosocial environment may mask genetic influences on
polygenic traits.
Introduction
Cannabis is the most common illicit drug used in the
US, and ~10–30% of cannabis users meet criteria for a
cannabis use disorder (CUD) at some point in their
lifetime1,2. Twin studies have suggested that individual
differences in cannabis use and CUD are due to genetic
(45–75%) and environmental factors3. Recent advances in
gene identification via genome-wide association studies
(GWASs) led by consortia and biobanks (e.g., Interna-
tional Cannabis Consortium (ICC)4, Psychiatric Geno-
mics Consortium, UK Biobank), combined with existing
theoretical frameworks for studying gene–environment
interaction (GxE)5, permit new ways of identifying
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contributions of common variants to cannabis use and
problems and allow for an evaluation of whether genetic
susceptibility to cannabis involvement varies in the con-
text of well-studied psychosocial risk and protective fac-
tors, such as trauma exposure and religiosity. This may
aid in our understanding of genetic influences on can-
nabis involvement and inform translation of genomics
findings into useful risk factor targets for public health
and clinical intervention.
Until recently, few studies have examined genetic risk
for cannabis involvement alone. Of the cannabis use and
CUD studies that have been published, few robust and
replicated genetic risk variants have been identified. A
GWAS of Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) cannabis-
dependence criterion count performed in three indepen-
dent substance-dependence cohorts (the Yale-Penn
Study, Study of Addiction: Genetics and Environment,
and International Consortium on the Genetics of Heroin
Dependence6) implicated three independent genomic
regions, including rs146091982, a variant within solute
carrier SLC35G1, a gene which encodes a protein involved
in cellular calcium levels; rs77378271, a variant within
CSMD1, a brain expressed gene of unknown function; and
in a novel antisense transcript RP11-206M11
(rs143244591). In addition, a recent meta-analysis of
GWAS on 2080 DSM-IV cannabis-dependent cases and
6435 cannabis-exposed controls identified a novel
genome-wide significant region on chromosome 10
(rs1409568)7, which the authors show may have a role as
an enhancer in addiction-relevant brain regions, such as
the dorsolateral prefrontal cortex and the angular and
cingulate gyri. Another recent GWAS of adults in Den-
mark and Iceland (iPSYCH) implicated a single-
nucleotide polymorphism (SNP; rs56372821) that is a
strong expression quantitative trait locus for CHRNA2
and that CHRNA2 expression in cerebellum is associated
with CUD8. Gene expression profiles in the Allan Brain
Atlas (http://www.brain-map.org/), which showed that, of
all the genes evaluated (58,692 probes analyzed), canna-
binoid receptor 1 gene (CNR1) demonstrated the stron-
gest negative correlation with CHRNA2 expression, led
the authors to suggest the possibility of a biological
interaction between the endocannabinoid system and
alpha-2 subunit containing nicotinic acetylcholine recep-
tor. Notably, there was no evidence of association of these
previously identified cannabis risk variants with CUD in
the iPSYCH study8. This might be due to different phe-
notype definitions among the studies: the Yale-Penn
study6 analyzed association with cannabis criterion
counts, and the cannabis-dependence meta-analysis7 used
cannabis-exposed individuals as controls in their study. In
addition, the composition of the cohorts analyzed also
differs: the previous GWASs6,7 were based on cohorts
established to study genetics of substance use disorders
while the iPSYCH cohort8 is ascertained for major mental
illnesses.
Larger GWAS sample sizes can be obtained by exam-
ining phenotypes that are less stringently defined and
therefore more likely available across genomic studies of
other outcomes. For example, the ICC published a meta-
analysis of genome-wide association data of 13 cohorts
(N= 32,330) and four replication samples (N= 5627) of
European ancestry (EA) assessed for cannabis use (i.e.,
having ever used cannabis in one’s lifetime)4. The ICC
meta-analysis included data from previous GWAS of
cannabis dependence6 described above. While no indivi-
dual SNP reached genome-wide significance, gene-based
tests identified four genes significantly associated with
lifetime cannabis use: NCAM1 and CADM2 (genes
involved in neural cell adhesion), short coiled-coil protein
(SCOC), and a potassium sodium-activated channel gene
(KCNT2). Furthermore, they demonstrated that all com-
mon SNPs explained 13–20% (p < 0.001) of the variance
in lifetime cannabis use. While several large studies and
consortia efforts to examine cannabis involvement are
underway, this is currently the largest peer-reviewed
meta-analysis of cannabis GWAS studies to date. A more
recent and larger meta-analysis (N: 184,765), including
data from the ICC (N: 35,297), 23andme (N: 22,683), and
the UK Biobank (N: 126,785), is now available from Pas-
man et al.9. The Pasman et al. study9 implicated CADM2
and NCAM1 and additional genetic risk loci for cannabis
ever use, including ZNF704 (zinc finger protein 704),
RABEP2 (Rabaptin, RAB GTPase Binding Effector Protein
2)/ATP2A1 (ATPase Sarcoplasmic/Endoplasmic Reticu-
lum Ca2+ Transporting 1), and ALDH2 (Aldehyde
Dehydrogenase 2 Family Member). While some genes
mentioned above have been previously identified via
genetic association studies with addiction related pheno-
types (e.g., ALDH2 and alcohol use disorders (AUDs)10),
the biological mechanisms linking these genetic variants
to cannabis use/abuse are largely unknown. Evidence that
there are both shared and non-shared genetic contribu-
tions to substance use and substance use disorders11
necessitates an examination of whether individual loci and
polygenic risk for cannabis ever use predicts progression
to cannabis use and problems (e.g., DSM-5 disorder cri-
teria) in independent samples. In addition, evidence that
genetic influences on other substance use and disorders
are modified by the social environment12,13 suggests that
key psychosocial factors may aid in our understanding of
genetic influences on cannabis involvement.
An early GxE study found that greater religiosity
diminished latent genetic influences on alcohol use
initiation14. Since then, genetically informed resilience
research has identified several aspects of religiosity as
important protective factors against substance use
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behaviors15–17, which may limit the expression of genetic
propensity for CUD. This can be interpreted in the con-
text of Shanahan and Hofer’s social context as social
control5, which refers to protective environments that
may attenuate a genetic predisposition toward a negative
outcome. In contrast, contextual triggering5 was used to
describe a detrimental environment combining with a
genetic predisposition toward a negative outcome. For
example, adverse experiences have been shown to
exacerbate genetic influences on substance use and dis-
orders18–20, including CUD17,21,22. We note that even the
association of Alcohol Dehydrogenase 1B (Class I), Beta
Polypeptide (ADH1B)-rs1229984 with alcohol use/pro-
blems, and Cholinergic Receptor Nicotinic Alpha 5 Sub-
unit (CHRNA5)-rs16969968 with cigarette smoking, two
of the most robust and replicable genetic effects in the
substance use literature, have been found to differ as a
function of trauma exposure13,23,24. However, critiques of
early GxE studies pointed to the likelihood of false posi-
tive findings given the focus on candidate genes and small
sample sizes typical of many well-characterized (i.e.,
deeply phenotyped) genetic studies, as well as other
important methodological considerations25. For example,
Keller26 illustrates the importance of accounting for
confounding effects of other two-way interaction terms
(e.g., G × covariate, E × covariate), which can complicate
the interpretation of regression-based GxE analyses.
Both cannabis use and CUDs are complex genetic traits,
influenced by multiple genetic variants of small effect (i.e.,
polygenicity) and aspects of the psychosocial environment
(e.g., religiosity, trauma), which act independently and in
concert. However, this information has not been effec-
tively incorporated into genetic association studies. Poly-
genic risk scores (PRS), which aggregate genetic variants
to reflect the underlying structure of complex traits, have
been increasingly used to model the genetic architecture
of substance use disorders12,13,27–30. In addition to the
potential for identifying genetic risk markers for cannabis
involvement31,32, these methods enable researchers to
identify potential psychosocial mechanisms that modify
genetic associations with CUD. Given that current find-
ings from psychiatric genomics research are not yet at the
point of clinical utility, identifying modifiable psychosocial
risk and protective factors may be useful for downstream
use in clinical and translational sciences.
Despite the number of studies that examine whether
adverse experiences or religiosity moderate genetic
influences on other substance use behavior (i.e., alcohol33,
nicotine13), no published GxE studies examine modera-
tion of genetic influences on CUD employing PRS derived
from large, recent genetic studies of cannabis behavior. In
this study, we use results from the Pasman et al. meta-
analysis of cannabis use to examine (1) whether genetic
propensity to cannabis use extends to cannabis problems
as measured by the DSM-5, and (2) whether two well-
established psychosocial factors known to influence sub-
stance use behavior, frequency of religious service atten-
dance and trauma exposure, moderate polygenic
influences on cannabis use and DSM-5 CUD symptoms in
an independent sample enriched with individuals at high
risk for substance use disorders.
Methods
Sample
The Collaborative Study on the Genetics of Alcoholism
(COGA) is a large family-based sample enriched for
alcohol and other substance use disorders34. COGA
recruited alcohol-dependent probands from inpatient and
outpatient AUD treatment facilities and comparison
subjects from the same communities. Probands and their
family members were interviewed with the Semi Struc-
tured Assessment of Alcoholism (SSAGA35,36). Informed
consent was obtained from all participants and institu-
tional review boards at all sites approved the study. For
further details, see ref. 34. The primary analytic sample
included 7591 individuals of EA, because the GWAS from
which PRS was calculated was based on EA. Secondary
analyses included 3359 individuals of African ancestry
(AA). A description of the analytic sample, including self-
reported “race/ethnicity” (correlation with genetic ances-
try= 0.95, p < 0.001) is in Table 1.
Genotyping and quality control
Genotyping of COGA samples were performed at (1)
the Center for Inherited Disease Research (1M array37),
(2) Genome Technology Access Center at Washington
University School of Medicine (Illumina OmniExpress38,
and (3) Rutgers University (Affymetrix Smokescreen
array39). All A/T and C/G SNPs were removed and a
common set of approximately 47,000 SNPs was used to
detect duplicate samples and to revise the reported ped-
igree structure. Family structures were altered as needed,
and SNP genotypes were tested for Mendelian incon-
sistencies40 within the revised family structure. Genotype
inconsistencies were set to missing. Imputation was to
1000 Genomes (Phase 3, version 5) using SHAPEIT41 and
then Minimac342 and performed separately within data
from the three genotyping sites. Only SNPs with a gen-
otype rate >75% were included in analyses. Further details
on the genotyping arrays, samples, and processing are in
Supplementary Information. To maximize the utility of
COGA’s family-based design, participants were assigned a
family-based ancestry of EA or AA, according to the
majority of individual-based ancestry in that family, based
on principal components (PCs) derived from GWAS data.
In the <10% of cases of equal proportion (e.g., 50% EA and
50% AA), the family was assigned the more heterogeneous
ancestry (AA). All analyses were conducted separately by
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ancestry, with ancestral PCs included as covariates in all
PRS analyses.
Genome-wide cannabis use PRS
We used genome-wide association estimates for can-
nabis ever use from the 2018 Pasman et al.9 meta-analysis
of GWAS data from the ICC and UK Biobank for ever use
of cannabis during one’s lifetime to calculate a cannabis
ever use PRS for participants in COGA. We used the
-score procedure in PLINK43, which computes a linear
function of the number of scored alleles an individual
possesses weighted by the associated GWAS beta coeffi-
cient. Matching SNPs were pruned for linkage dis-
equilibrium (LD) based on 1000 Genome phase 3
reference panel genotype data for EA for EA participants
and AA for AA participants, with clumping based on the
Pasman et al. GWAS p values using a 500-kb physical
distance and an LD threshold of r2 ≥ 0.25. We note that
the Pasman et al. study9 is entirely of EA. Because of this,
genetic influences captured in this PRS will likely predict
cannabis use behavior in AA samples poorly44. Therefore,
the current manuscript focuses on COGA’s EA partici-
pants. However, COGA includes one of the largest
genetically informative AA samples available. We there-
fore conducted a series of exploratory analyses in 3359
AA participants to test the predictive power of EA-based
summary statistics in an AA population (Supplementary
Table 2). Secondary analyses conducted in the AA parti-
cipants followed the same procedures as described for EA
participants. We calculated a series of scores in our
sample that included SNPs meeting increasingly stringent
p value thresholds (p < 0.0001, p < 0.001, p < 0.01, p < 0.05,
p < 0.10, p < 0.20, p < 0.30, p < 0.40, p < 0.50) in the
discovery GWAS.
Measures
Cannabis use was assessed with the following question:
“Have you ever used marijuana or hashish?” Response
options were Yes (1) or No (0). DSM-5 CUD symptoms
were derived from the SSAGA and included
0–11 symptoms, including: tolerance, withdrawal, activ-
ities given up due to cannabis use, time dominated by
cannabis use, cannabis use despite physical or psycholo-
gical consequences, craving, etc. Among individuals with
more than one interview, data from the most recent
interview with the maximum number of CUD symptoms
was used.
Frequency of religious service attendance was assessed
with the following question: In the past 12 months, how
many times did you attend religious services? Response
options ranged from 0 to 365. Values were log-
transformed. Sensitivity analyses also tested “any
Table 1 Description of the analytic sample, a subset of the Collaborative Study on the Genetics of Alcoholism
All participants (N: 10,954) European ancestry (N: 7599) African ancestry (N: 3355)
Female 5805 3998 1807
Age at most recent interview Range: 12–91 years; M: 35.61
(SD: 14.18)
Range: 12–91 years; M: 36.77
(SD: 14.83)
Range: 12–84 years; M: 32.88
(SD: 12.16)
Self-reported race
White/Caucasian 7655 7454 201
Black/African American 2920 11 2908
Asian 29 11 18
Hispanic/Latino 619 207 412
Native American/American Indian/Pacific Islander/
Other (non-specified)
357 127 230
Unknown 3 1 2
Trauma exposure 1443 847 596
Non-assaultive 1207 703 504
Assaultive 714 383 331
Sexually assaultive 264 165 99
Frequency of religious service attendance during
12 months prior to interview
Range: 0–356 days; M: 16.22
(SD: 33.89)
Range: 0–356 days; M: 15.88
(SD: 33.74)
Range: 0–260 days; M: 17.50
(SD: 34.89)
Cannabis use 7546 5014 2532
DSM-5 cannabis use disorder symptom count Range: 0–11; M: 1.69 (SD: 2.83) Range: 0–11; M: 1.58 (SD: 2.78) Range: 0–11; M: 1.92 (SD: 2.90)
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attendance” (0 vs. other values) and “weekly” attendance
(values ≥52 vs. values <52), and models stratified by
attendance before and after age 18 years. In addition,
participants were asked about their religious preference
and given the following response options: Catholic, Pro-
testant (e.g., non-fundamentalist Baptist, Episcopalian,
Lutheran, Methodist, Presbyterian), Fundamentalist Pro-
testant (e.g., Assembly of God, fundamentalist Baptist,
Brethren, Evangelical Christian, Foursquare Gospel
Church, Jehovah’s Witness, Nazarene, Pentecostal), Jew-
ish, Moslem, Buddhist, Not affiliated, Agnostic, Atheist,
Other (e.g., B’hai, Hindu, Unitarian, Wicca), Greek-,
Serbian-, Russian-Orthodox, Christian, other (e.g., Char-
ismatic, Christian Scientist, Mennonite, Mormon, Seventh
Day Adventist), Christian, not otherwise specified.
Two different SSAGA assessments were used to ascer-
tain trauma exposure data in the current study. In all,
58.6% (N: 3875) of the EA analytic sample had trauma
assessed using the SSAGA-IV35 as described previously45.
Briefly, the SSAGA-IV post-traumatic stress disorder
section begins by asking participants about “terrible,
frightening, or horrible experiences” they may have had in
their lifetime. Subsequently, they are asked about having
ever experienced 21 specific potentially traumatic events,
including assaultive, non-assaultive, and sexually assaul-
tive exposures (detailed in Supplementary Table 3).
Trauma exposure data on an additional 2738 participants
was ascertained from earlier waves of the COGA study in
which the SSAGA-II was used. The SSAGA-II asked
participants if they “had ever experienced or witnessed
something that is so horrible that it would be distressing
or upsetting to almost anyone?” The SSAGA-II then listed
some examples of potentially traumatic events and asked
the participant to list up to three events. In order to use
available trauma exposure data from both the SSAGA-IV
and SSAGA-II, we examined a binary measure of trauma
exposure (0: not exposed, 1: exposed), based on SSAGA-II
and SSAGA-IV responses, to maximize statistical power,
which is especially crucial in GxE studies. All individuals
who were not interviewed using the SSAGA-II or
SSAGA-IV and hence were not asked about trauma
exposure were coded as “unknown” and excluded from
PRS × trauma analyses. As compared to those with avail-
able trauma data (N: 6613), those with missing data
related to trauma exposure (“unknown”, N: 4341) were
more likely to be older and “White/Caucasian.”
Statistical analysis
In independent models, cannabis use ever (0: never, 1:
ever use) and DSM-5 CUD symptom counts
(0–11 symptoms, log-transformed) were regressed using
Poisson models on cannabis ever use PRS from the Pas-
man et al. study9. Models were adjusted for ancestral PCs
(PC1–PC3), age (range: 12–91 years; mean= 36.77, SD:
14.83), birth cohort (dummy variables representing birth
years prior to 1930, 1930–1949, 1950–1969, and 1970 and
after), and sex (0=male, 1= female), given prior evidence
that cannabis use and problems differ across these
groups46. In addition, genotype array was used as a cov-
ariate in all analyses since different platforms were used
across the sample (detailed above). In addition, we
accounted for the nested nature of the family-based
sample in all regression analyses using hierarchical multi-
level modeling. A Bonferroni correction for multiple
testing, adjusting for two cannabis-related outcomes and
nine PRS thresholds was applied to all findings, requiring
a p value < 0.003 to meet criteria for statistical sig-
nificance. Cannabis use and CUD were moderately cor-
related (r2: 0.40, p < 0.001); PRS across varying thresholds
were only modestly correlated (r2 ranged from 0.04 to
0.07). To further reduce the multiple test burden, mod-
eration analyses were only conducted with those PRS for
which a significant main effect on cannabis use and/or
CUD symptom count (CUDsx) was observed. When sig-
nificant main effects of the PRS were observed, we tested
for multiplicative interactions with trauma exposure and
frequency of religious service attendance. When sig-
nificant main effects of the PRS were observed, we tested
for multiplicative interactions with trauma exposure and
frequency of religious service attendance. Note that only
individuals who reported ever using cannabis in their
lifetime were included in DSM-5 CUDsx analyses. All
other individuals were classified as unknown and were not
included in analyses of CUD symptoms. Sensitivity ana-
lyses including these individuals were conducted as well
to examine the influence of excluding these individuals in
our analyses. In addition, secondary models included
cross-terms for all variables included in the interaction
models (e.g., Model 2 included PRS × trauma, PRS × age,
PRS × sex, PRS × birth cohort, PRS × PCs 1–3, trauma ×
age, trauma × sex, trauma × birth cohort, trauma × PCs
1–3, etc.) as suggested by Keller26.
Results
Of the primary analytic sample (i.e., EA participants
with GWAS data, n= 7591), 66.3% had ever used can-
nabis in their lifetime, and 28.2% met criteria for lifetime
DSM-5 CUD [mild (2–3 criteria; 8.8%), moderate (4–5
criteria; 6.9%), severe (6+ criteria; 12.4%)]. Among those
who had ever used cannabis in their lifetime, 42.6% met
criteria for lifetime DSM-5 CUD [mild (13.6%), moderate
(10.6%), severe (18.4%)]. Among cannabis users, mean
number of CUD symptoms was 2.39 (Range: 0–11, SD:
3.14). A greater number of symptoms were observed
among men and younger individuals.
Among EAs, main effects of the PRS were observed for
cannabis ever use and for DSM-5 CUDsx (Table 2; Fig. 1):
PRS with p < 0.05, p < 0.10, p < 0.20, p < 0.30, p < 0.40, and
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p < 0.50 thresholds were nominally associated with ever
cannabis use (p ranging from 0.009 to 0.001) and PRS
with p < 0.001, p < 0.01, p < 0.05, p < 0.10, p < 0.20, p <
0.30, p < 0.40, and p < 0.50 thresholds were associated
with DSM-5 CUDsx (p ranging from 0.036 to 0.001), but
only nominally in ever users (p ranging from 0.043 to
0.005). Associations of PRS (p < 0.05 threshold) with ever
cannabis use and PRS (p < 0.10 threshold) with DSM-5
CUDsx withstood a Bonferonni correction for multiple
testing. Above and beyond the aggregate effects of the sex,
birth cohort, genotype array, and ancestral PCs, the PRS
with p < 0.05 accounted for 0.2% of the variance in ever
cannabis use (area under the curve (AUC): 0.53 (0.52,
0.54)) and 0.2% of the variance in DSM-5 CUDsx (DSM-5
CUD diagnosis AUC: 0.51 (0.48, 0.55)) (Table 2). No main
effects of the PRS were observed for ever use of cannabis
or for DSM-5 CUDsx among AA participants (Supple-
mentary Table 2).
Trauma exposure
Data on trauma exposure was available for analysis on
6613 EA individuals. Lifetime trauma exposure was
reported by 12.8% of the sample. Note, trauma exposure
was reported by 12.3% of those assessed with the SSAGA-
IV (full trauma checklist, Supplementary Table 3) and
15.4% of those assessed with an earlier SSAGA (abbre-
viated, as described above). Trauma exposure was asso-
ciated with cannabis use (B: 0.065, p < 0.017, R2: 0.004)
Table 2 Main effects of cannabis initiation polygenic risk scores on cannabis use and DSM-5 cannabis use disorder
symptom count in COGA participants of European ancestry
Threshold Cannabis use ever (lifetime) DSM-5 cannabis use disorder
symptom count
DSM-5 cannabis use disorder
symptom count (among
cannabis users)
R2 Beta p value R2 Beta p value R2 Beta p value
p < 0.0001 0.000 0.018 0.200 0.000 0.004 0.769 0.000 0.015 0.428
p < 0.001 0.001 0.029 0.050 0.001 0.032 0.036 0.001 0.037 0.059
p < 0.01 0.001 0.028 0.050 0.000 0.019 0.222 0.000 0.023 0.249
p < 0.05 0.002 0.046 0.001** 0.002 0.041 0.007 0.002 0.039 0.043
p < 0.1 0.001 0.039 0.006 0.002 0.050 0.001** 0.003 0.055 0.005
p < 0.2 0.001 0.039 0.007 0.001 0.040 0.010 0.002 0.041 0.038
p < 0.3 0.001 0.042 0.004 0.001 0.040 0.011 0.002 0.042 0.037
p < 0.4 0.001 0.040 0.006 0.002 0.041 0.009 0.002 0.044 0.029
p < 0.5 0.001 0.038 0.009 0.002 0.041 0.009 0.002 0.045 0.025
Note: Polygenic risk scores are derived from Pasman et al.’s cannabis initiation GWAS4 summary statistics. Covariates include sex, age, birth cohort, genotype array,
PCs 1–3. Boldface indicates estimates that are statistically significant with p < 0.05; double asterisks (**) indicate estimates that withstand Bonferroni test correction
(0.05/27= 0.0018)
0.0000
0.0010
0.0020
0.0030
Cannabis use ever DSM-5 CUD Symptom
Count
DSM-5 CUD Symptom
Count (Cannabis Users)
ps
eu
do
 R
2
p<0.0001
p<0.001
p<0.01
p<0.05
p<0.1
p<0.2
p<0.3
p<0.4
p<0.5
****
**
Fig. 1 Main effects of cannabis ever use polygenic risk scores on cannabis use and DSM-5 cannabis use disorder symptom count in COGA
participants of European ancestry. Double asterisks (**) denote associations that withstand a multiple test correction
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and DSM-5 CUDsx (B: 0.161, p < 0.0001, R2: 0.026);
trauma exposure was more common in cannabis users
(12.9%) compared with non-users (7.6%) and in those
meeting criteria for DSM-5 CUD (15.8%). Trauma expo-
sure also moderated the association of the PRS (p < 0.05
threshold) with cannabis ever use in both Model 1, which
adjusted for age, sex, birth cohort, genotype array, and
genetic ancestry, and Model 2, which also included two-
way interactions for all variables included in the model
(Table 3). Interactions among trauma exposure and PRS
with p < 0.05 and p < 0.10 thresholds were observed for
cannabis ever use but not DSM-5 CUDsx (Table 3). Both
PRS had a greater influence on cannabis ever use and
DSM-5 CUDsx among those exposed to trauma (R2:
0.011–0.014; AUC: 0.58 (0.53, 0.62)) as compared to those
who were not exposed to trauma (R2: 0.001–0.002; AUC:
0.49 (0.43, 0.54), Fig. 2a). Trauma exposure was not pre-
dicted by cannabis use PRS (p > 0.26).
Religiosity
In all, 66.5% of the full sample reported any attendance
at religious services in the past 12 months. While 29% of
the analytic sample did not specify their religious affilia-
tion, and 19.7% reported “no affiliation, agnostic, or
atheist,” 18.9% reported their affiliation as Christian,
15.3% Catholic, 9.7% Protestant, and 4.8% Fundamentalist
Protestant. All other affiliations (Jewish, Moslem, Bud-
dhist, etc.) were reported by <1% of the sample. Within
the analytic sample, 12.6% of participants reported that
they affiliated with a religion that had rules forbidding
alcohol use; these participants were most likely to identify
as Christian (broadly), followed by Protestant or Funda-
mentalist Protestant and Buddhist. The mean number of
days of service attendance was 15.9 (SD: 33.74) days
within the 12 months prior to the interview. Both can-
nabis ever use (B: −0.185, p < 0.001, R2: 0.052) and DSM-5
CUDsx (B: −0.099, p < 0.001, R2: 0.058) were associated
with frequency of religious service attendance; any service
attendance was less common in cannabis users (61.9%)
than in non-users (81.0%) and in those meeting criteria
for DSM-5 CUD (50.5%). Similar patterns were observed
for any attendance (cannabis use: B: −0.124, p < 0.001, R2:
0.015; CUDsx: B: −0.136, p < 0.001, R2: 0.018) and weekly
attendance (cannabis use: B: −0.214, p < 0.001, R2: 0.045;
CUDsx: B: −0.135, p < 0.001, R2: 0.018). Frequency of
religious service attendance moderated the association of
the PRS with cannabis ever use and DSM-5 CUDsx but in
the models that adjusted for age, sex, birth cohort, and
ancestral PCs only (Model 1, Table 3). For cannabis ever
use, interactions were observed between frequency of
religious service attendance and PRS (p < 0.05 and p < 0.10
thresholds), and for DSM-5, interaction was observed
between frequency of religious service attendance and
PRS (p < 0.10 threshold). All PRS had a greater influence
on cannabis ever use and DSM-5 CUDsx among those
who less frequently attended religious services as com-
pared to those who more frequently attended services
(Fig. 2b). However, in models that also included cross-
terms for all variables in the interaction model, no sig-
nificant moderation effects were observed (Model 2, Table 3).
Post hoc step-wise models indicated that the interaction
among frequency of service attendance and the PRS was
diminished by the inclusion of sex × religious service
attendance frequency (however, the PRS by service
attendance frequency interaction remained statistically
Table 3 Moderation of cannabis use and DSM-5 CUD
symptom count by trauma exposure and frequency of
religious service attendance among COGA participants of
European ancestry; results from Model 1 that includes the
following covariates: age, sex, birth cohort, genotype
array, and PCs 1–3
PRS threshold Cannabis use ever
(lifetime)
DSM-5 cannabis use
disorder Sx count
R2 Beta p value R2 Beta p value
Trauma exposure × PRS
p < 0.0001 — — — — — —
p < 0.001 — — — — — —
p < 0.01 — — — — — —
p < 0.05 0.005 0.181 0.009a 0.001 0.098 0.148
p < 0.1 0.004 0.341 0.016 0.001 0.115 0.406
p < 0.2 — — — — — —
p < 0.3 — — — — — —
p < 0.4 — — — — — —
p < 0.5 — — — — — —
Frequency of service attendance × PRS
p < 0.0001 — — — — — —
p < 0.001 — — — — — —
p < 0.01 — — — — — —
p < 0.05 0.008 0.281 0.006 0.004 0.194 0.061
p < 0.1 0.007 0.448 0.014 0.008 0.476 0.010
p < 0.2 — — — — — —
p < 0.3 — — — — — —
p < 0.4 — — — — — —
p < 0.5 — — — — — —
Moderation analyses were only conducted on scores where a statistically
significant (p < 0.002) main effect was observed. Boldface indicates estimates
with p value < 0.05
aDenotes results that were statistically significant in Model 2, which includes the
following covariates: age, sex, birth cohort, PCs1–3, PRS × trauma/frequency of
service attendance, PRS × age, PRS × sex, PRS × PCs 1–3, trauma/frequency of
service attendance × age, trauma/frequency of service attendance × sex,
trauma × PCs 1–3. Data from Model 2 are displayed in Supplementary Table 1
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significant, p < 0.037). The inclusion of the ancestral PC1
by religious service attendance frequency interaction sig-
nificantly reduced the variance explained by this model
(p > 0.30). Sensitivity analyses were conducted stratified
by age (above and below age 18 years) to determine
whether effects differed by age; similar results were
observed for those under and over age 18 years. Religious
service attendance was unrelated to cannabis use PRS
(p > 0.14). However, the first genetic ancestral component
(PC1) was positively correlated with Jewish religious
affiliations (r: 0.39, p < 0.0001) and negatively correlated
with Protestant religious affiliations (r: −0.14, p < 0.0001).
Discussion
The current study demonstrates that polygenic liability
to cannabis use was nominally associated with cannabis
use (ever) and with DSM-5 CUDsx in COGA, a deeply
phenotyped family sample enriched for individuals with
substance use disorders. In addition, moderation of this
polygenic risk for cannabis use was observed with one
well-known risk factor, trauma exposure. Weaker evi-
dence of moderation by frequency of religious service
attendance was also observed. These findings provide the
first evidence that trauma may potentiate polygenic risk
for CUDs, while for some groups, religious service
attendance may serve to dampen genetic susceptibility.
Our study extends the GxE literature on trauma expo-
sure and cannabis use substantially. Previous studies have
shown that different types of trauma exposure (physical
assault, sexual assault, etc.) significantly increase risk for
CUD20,46 and that adverse experiences exacerbate genetic
influences on alcohol and drug use behaviors47. To our
knowledge, this is among the first studies to document the
role of lifetime trauma in accentuating polygenic risk to
cannabis use. Our results indicate that the influence of
polygenic risk on cannabis use accounts for ~1–2% of the
variance in CUD symptoms among those who are exposed
to trauma as compared with 0.1–0.2% among those who
(A) 
(B) 
0.000
0.004
0.008
0.012
Main Effect No Trauma Trauma Main Effect No Trauma Trauma
Cannabis use ever DSM-5 Cannabis Use Disorder Symptom
Count
ps
eu
do
 R
2
p<0.01
p<0.05
0.000
0.004
0.008
0.012
Main Effect <weekly
service
attendance
>weekly
service
attendance
Main Effect <weekly
service
attendance
>weekly
service
attendance
Cannabis use ever DSM-5 Cannabis Use Disorder Symptom
Count
ps
eu
do
 R
2
p<0.01
p<0.05
Fig. 2 Main effects of PRS (p < 0.01 and p < 0.05 p value thresholds) and PRS effects stratified by trauma exposure (no trauma = not
exposed to a traumatic event; trauma = exposed to a traumatic event) and frequency of weekly religious service attendance. Main effects
of PRS (p < 0.01 and p < 0.05 p value thresholds) and PRS effects stratified by trauma exposure (no trauma= not exposed to a traumatic event;
trauma= exposed to a traumatic event) are displayed in a. Main effects of PRS (p < 0.01 and p < 0.05 p value thresholds) and PRS effects stratified by
frequency of weekly religious service attendance are displayed in b. PRS had a greater influence on cannabis ever use and DSM-5 CUD symptom
count among those who had been exposed to traumatic events (a) and among those who less frequently attended religious services (b)
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are not exposed to trauma. Future genetic studies with
larger sample sizes should examine the PRS × trauma
exposure effects on substance use behavior considering
specific types of trauma, age of trauma exposure, and
duration and frequency of trauma exposure to gain fur-
ther understanding of these findings.
Consistent with previous studies48, we observed that
individuals who more frequently attended religious ser-
vices were less likely to use cannabis in their lifetime and
endorsed fewer DSM-5 CUD symptoms. Epidemiological
research has identified several aspects of religiosity as
important protective factors against substance use pro-
blems. For example, religious service attendance provides
both interpersonal and community social support that
may serve to increase resiliency and limit expression of
genetic propensity to cannabis use. In addition, protective
effects of religion may be mediated by the degree to which
specific religions foster restrictive social norms and atti-
tudes regarding substance use49. In this study, 12.6% of
participants reported that they affiliated with a religion
that had rules forbidding alcohol use; these participants
were most likely to identify as Christian (broadly), fol-
lowed by Protestant or Fundamentalist Protestant and
Buddhist. We note, however, that, while there may be
religious proscriptions regarding alcohol use, these may or
may not extend to cannabis use. Further, some twin stu-
dies have shown that aspects of religiosity moderate
genetic influences on alcohol use behavior19–22. For
example, a Dutch twin study found that, among women
without a religious upbringing, genetic influences
accounted for 40% of the variance in alcohol use ever
compared to 0% among women raised religiously. Con-
versely, church attendance was not a moderator of genetic
influences on adolescent alcohol consumption among
adult male twins from Virginia, suggesting that findings
may differ as a function of sex and culture. The current
study expands this literature by providing evidence that
the influence of cannabis use PRS on cannabis use and
DSM-5 CUD symptoms is moderated by frequency of
religious service attendance in a cohort of males and
females between ages 12 and 91 years. We note, however,
that none of these findings withstood a multiple test
correction. Interestingly, while studies have shown that
religious service attendance during adulthood may be a
more robust safeguard against heavy substance use and
may reflect innate tendencies toward religious affiliations,
relative to childhood attendance that bears a strong
familial component45, our findings did not differ sig-
nificantly when analyses were stratified by age. In addi-
tion, since social support (outside of the religious context)
has also been identified as an important protective factor
against alcohol and other drug use50 and has been shown
to diminish genetic risk for other substance use pro-
blems13, social and community aspects of religiosity, likely
captured by frequency of religious service attendance,
may be an important moderator of cannabis use.
Keller notes that ignoring two-way interactions between
the environmental measure and other covariate terms in
GxE analyses can generate spurious findings42. Upon
addition of these two-way terms, the moderating effect of
religious service attendance was diminished by the
inclusion of interactions between service attendance fre-
quency and the first ancestral PC and with sex. Interest-
ingly, within the EA analytic sample, PC1 is significantly
positively correlated with Jewish religious affiliations (r:
0.39, p < 0.0001) and negatively correlated with Protestant
(non-fundamentalist Baptist, Episcopalian, Lutheran,
Methodist, Presbyterian) religious affiliations (r: −0.14, p
< 0.0001). The influence of ancestral PC1 is likely
reflecting both cultural differences regarding cannabis use
by ancestral background (i.e., country of origin) within
European Americans and differences by religious affilia-
tion in attitudes toward cannabis use demonstrated by
previous studies48,51,52. In addition, religious service
attendance was a more prominent buffer from CUD
among women relative to men, which is supported by
previous studies that have shown the inverse associations
of religiosity and substance use behavior are greater
among women relative to men48,51,52.
There are several strengths of this study. We
demonstrated polygenic effects of common genetic
variation on cannabis use, with weaker associations
observed with persistence into DSM-CUD symptoms, in
a well-characterized sample enriched for substance use
problems. This provides molecular polygenic support
for some genetic distinction of cannabis use and CUD
demonstrated in several twin studies3. In addition, we
used a relatively novel approach by testing GxE using
polygenic scores, which allowed a focus on how poly-
genic influences on cannabis involvement differ as a
function of psychosocial context. Further, we responded
to critiques of GxE studies, which largely do not account
for potential confounding of GxE effects25,26. Specifi-
cally, modeling of cross-term interactions revealed
important influences of ancestry and sex on the PRS ×
frequency of religious service attendance effects
observed in the current study. It should be noted that,
while this study utilized genetic data to assign ancestry,
which in our analytic sample was highly correlated with
self-reported “race/ethnicity” (r: 0.95, p < 0.001), these
are distinct constructs both shown to influence risk of
substance use-related health outcomes, namely, through
interactions with the psychosocial environment. In our
data, the addition of self-reported “race/ethnicity” does
not provide additional explanatory value, over and
above genetic ancestry. Future PolyGxE studies should
consider the role of other important social and cultural
constructs.
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Despite its strengths, our results should be interpreted
within the context of the following limitations. The pre-
sent analysis uses retrospective reports of substance use
and traumatic life events and relies on measures of past
year religiosity. The temporality of associations observed
in this study is ambiguous; that is, the timing of traumatic
exposures and religious service attendance with regard to
cannabis use behaviors was not considered in the present
study. While this study has largely focused on inter-
pretations that assume trauma exposure and religious
service attendance preceded cannabis use problems, pre-
vious studies show that substance use and problems may
also precede both trauma exposure and religious service
practices. Timing of traumatic exposure, religious service
attendance, and cannabis use behaviors should be used to
further understanding of the temporality of these asso-
ciations. In addition, this study focused on participants of
EA due to the ancestral composition of the discovery
cohorts in the Pasman et al. study9. While congruent with
what is expected for PRS derived from GWASs with
sample sizes and effect sizes similar to those observed in
Pasman et al.9, predictive power of the PRS observed in
this study was poor or non-significant for CUDsx. Given
the reliance of PRS on large, well-powered samples, future
studies should re-examine the relations examined in this
study with larger studies that will soon be available to the
research community. In addition, GWAS that specifically
examine problematic cannabis use may be needed to
achieve predictive utility for CUD. Finally, these findings
may not be generalizable to individuals of other ancestral
backgrounds as seen in our AA cohort (Supplementary
Table 2). While Supplementary Table 2 shows the pre-
diction of cannabis use and CUDsx in COGA’s partici-
pants of AA, we note the limitations of applying EA-
derived summary statistics to participants of AA. Large
discovery GWAS in non-Europeans could be foundational
in bridging the disparity in PRS research that is heavily
weighted toward European populations even though
negative consequences of addictions disproportionately
impact those from other ancestral backgrounds53.
Although evidence for GxE on substance use behavior
has been well established, translation of this research into
useful risk-factor targets for public health and clinical
intervention is lacking. Among the reasons is the complex
etiology of cannabis use and problems, which involves
multiple genetic and psychosocial influences, each having
very subtle effects. Despite this challenge, evidence for the
influence of GxEs on substance use behaviors is mount-
ing. In this study, we show that polygenic liability to
cannabis ever use predicted cannabis use but not pro-
gression to DSM-5 CUDsx in COGA. However, this
accounts for an extremely limited (∼0.2%) portion of the
total variance in cannabis use. Among the trauma
exposed, this increased to ~1.4% of the total variance in
cannabis use. Given the limited predictive utility of cur-
rent genetic information for cannabis use and CUD, it is
important to note that both of the psychosocial contexts
measured in this study explained a significantly greater
portion of the variance in CUD as compared with the PRS
(trauma exposure R2: 0.026; frequency of service atten-
dance R2: 0.058). Findings from this study suggest that
clinicians should pay particular attention to the possible
escalation of cannabis use and misuse in those with
genetic susceptibility and a history of trauma exposure.
Treatment approaches that are tailored toward both
prevention of CUD and ameliorating the burden of prior
experienced trauma require continued care and mon-
itoring. Encouragingly, regular engagement in religious
services, at least within some communities, is likely to
dampen the influence of genetic vulnerability. It is likely
that other forms of prosocial engagement perform a
similar protective function. Therefore, prevention strate-
gies that encourage such pro-social engagement is war-
ranted in vulnerable populations, such as those exposed to
trauma. Though we note that alternative explanations for
this study’s findings (e.g., confounding by sex and/or
ethnicity, the influence of cannabis use, and problems on
religiosity) cannot be ruled out.
In conclusion, polygenic liability to cannabis use was
nominally associated with cannabis ever use and with
progression to DSM-5 CUDsx in an independent sample
of individuals enriched for substance use problems. In
addition, PRSxE was observed with trauma exposure, with
less consistent moderation effects observed with religious
service attendance that are driven by important interac-
tions with ancestry and sex. These findings provide the
first evidence of PRSxE effects for cannabis use and sup-
port previous findings that trauma exacerbates genetic
risk for substance use, while religious service attendance
may serve as a protective factor. This study also demon-
strates that, by not modeling important aspects of the
psychosocial environment, we may mask genetic influ-
ences on polygenic traits, such as cannabis use.
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